South Korea’s botulinum toxin industry, a key pillar of its bio-sector, faces existential risk from a controversial 'National Core Technology' designation that experts say lacks legal and technical basis. With a review by the Ministry of Trade, Industry and Energy’s biotechnology committee imminent, the designation’s removal is widely expected—but vested interests are mounting distortion campaigns to block it.
Regulatory flaws exposed
Parliamentary audits in 2024 and 2025 revealed that the designation process for botulinum toxin as a National Core Technology was marred by missing public hearing documents and the absence of a regulatory impact assessment. Most critically, the Office for Government Policy Coordination confirmed that the agenda was never submitted to the Regulatory Reform Committee for review—a procedural omission that legal experts call a fundamental breach of the Framework Act on Administrative Regulations and the Administrative Procedures Act.
Technical mismatch with core technology definition
Botulinum toxin is a widely commercialized generic technology, with over 40 products approved in about 10 countries including the U.S., Europe, Israel, Russia, China, and Iran. GenBank lists more than 2,200 toxin strains globally. Industry observers argue that treating this as a 'core technology' comparable to jet engines or space reentry systems is a policy distortion that stifles business without serving national security.
Industry and legal pushback
Two long-serving committee members who championed the designation were dismissed in January 2025 after parliamentary criticism. Industry insiders suspect they may have acted to protect specific vested interests. Calls are growing for the Ministry of Trade, Industry and Energy to launch an internal investigation and for the Board of Audit and Inspection to review the officials’ conduct. Surveys by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association and the Korea Civic Education Alliance show 78% and 82% support for removing the designation, respectively.
What buyers should watch
Overseas buyers should monitor the upcoming biotechnology committee review, expected within weeks. If the designation is lifted, South Korean toxin manufacturers will gain more freedom to export and collaborate globally, potentially increasing supply options and reducing costs. Conversely, continued designation may limit Korean suppliers’ ability to compete, affecting pricing and availability for international distributors and clinics.
Sourcing context
South Korea is a major producer of botulinum toxin products, with over 20 domestic manufacturers and sellers. The current regulatory burden forces some firms to pay royalties for foreign strains while being restricted from global markets. Removal of the designation could unlock greater innovation and export capacity, benefiting the entire medical aesthetics supply chain.
Source: Read the original report | Published: June 12, 2026